Hear from Eli Lilly, J&J, and Celgene on FFS, GP, AMP and more

At IIR’s 6th Annual Government Programs Summit, we provide you with varying perspectives on the way ACA ramifications have profound impact on the way you do business through engaging and interactive panel discussions. The following sessions—led by industry thought leaders and regulators will prepare you for the massive set of changes to the way the MDRP program is managed:

Developments in the Split between Managed Medicaid and Fee-For-Service
Josh O’Harra, Asst. General Counsel, Eli Lilly and Company
Andy Vasquez, Deputy Director, Texas Health & Human Services Commission (Invited)
Steve Liles, Pharm.D., Senior Director, Pharmacy Services, Goold Health Systems
Patricia Tietbohl, Director, Government Rebate Operations, Johnson & Johnson

What the GP Professional, Senior Management and the Board, Need to Be Aware of in a Merger or Acquisition
Chris Cobourn, Senior Vice President, Commercial Compliance, Compliance Implementation Services
Additional Panelists to be announced

Identifying How the AMP Final Rule Impacts Business Objectives and Developing an Adjustment Approach
Frank Prybeck, Director, Federal Government Pricing & Contract Administration, Celgene
Heather Dixson, Director, Government Price Reporting, Lilly USA, LLC 
Eric Lewis, Manager, Government Programs & Compliance, Baxter Healthcare Corporation 
Ken Nelson, Director, Johnson & Johnson 

Continually Strengthening Collaboration between States and Manufacturers
John Grotton, R.Ph., Executive Vice President, Goold Health Systems
Lisa Marchisello-Norton, Associated Consultant, Managed Healthcare Services, Lilly USA, LLC 
David Buckley, Contract Operations Mgr, Contract Management and Operations US, GlaxoSmithKline Cemeria M. Ehis, Pharmacy Rebate Analyst, Alabama XIX, HP Enterprise Services

To learn more, download our agenda.

Register with code XP1951BLOG and receive 15% off of the standard rate. If you have any questions about the event, feel free to contact Kate Devery (Kdevery@iirusa.com) For more information visit our homepage.

We hope to see this March!

Cheers,
The Government Programs Team

Opt-in for GP updates
GP Twitter
GP LinkedIn

New Discussion Groups for Big, Small, Mid-Sized Pharma & Generics

Ensuring your Gross-to-Net calculations are accurate is a messy business, and now more than ever, enormous complexity exists due to a shifting payer mix stemming from healthcare reform.

At IIR’s 2nd Annual Gross-to-Net Accounting Forum, we know how important it is for you to be able to benchmark your systems and methodologies against best practices—and that the calculations are very different for large, small to mid-sized pharma, and generic companies. For that reason, we are introducing new unique tailored discussion groups specific to your company size and function where you can discuss and share challenges with like-minded peers.

Collaborate across managed markets, commercial, government programs and finance with your dedicated discussion group leaders:

• Big Pharma – Courtney Callihan, Finance Director, GlaxoSmithKline
• Small to Mid-Sized Pharma – Larry Breen, Director of Financial Planning and Analysis, Sunovion Pharmaceuticals
• Generics – Roxana Santiago, Senior Finance Manager Gross to Net, Hospira Worldwide, Inc. 

To full our full program, download the 2014 brochure.

Register today using code XP1911BLOG and receive 15% off the standard rate. If you have any questions about the agenda or event, please contact Kate Devery at kdevery@iirusa.com or visit our webpage. We look forward to seeing you June 17-18 in Philadelphia!

Best,
The GTN Team

Opt-in for updates
Follow us on Twitter
GTN LinkedIn

HRSA’s 340B Program Update, Managing the Coverage Gap, and a Full-Day of Final Rule Insight at IIR’s 6th Annual Government Programs Summit

At IIR’s 6th Annual Government Programs happening March 26-28, 2014 in Alexandria, prepare for the impact of the U.S. Department of Health and Human Services June publishing of the 340B proposed rule and get practical solutions to manage the Coverage Gap Discount Program (CGDP) challenges.

Understand the rebates and forecasting involvement with the new Part D requirements in the session, Practical Solutions Manufacturers can use to Manage Coverage Gap Discount Program Challenges and hear from Cmdr. Krista M. Pedley, PharmD, MS, CDR, USPHS, Director, Office of Pharmacy Affairs, Health Resources and Services Administration, update the 340B program. Want more? Learn about the latest hot topic areas: Contract Pharmacies, Orphan Drugs, GPO Prohibition, Covered Outpatient Drugs, and Audits in the track — 340B Summit for Manufacturers, in collaboration with Apexus' 340B University.

New Podcast: Preview the Advanced GP Forum and Get Industry Insights from Chris Cobourn, SVP at CIS as he provides industry insights to:

• How manufacturers can navigate the challenge of forecasting Medicaid and Medicaid Managed Care
• Lessons learned on Bona Fide Service Fees and Fair Market Value
• The role of the GP professional evolving in a merger acquisition

Plus! Get a sneak preview from Chris on the one-of-a-kind Advanced GP Forum — Fiscal and Methodological Considerations of the Final Rule pre-conference day workshop, where you will receive a unique opportunity to obtain insights on critical GP issues from a panel of industry thought leaders. This full-day panel discussion will prepare for the individual components of the Final Rule and also discuss obtaining intelligence for planning and forecasting.

Listen to the full podcast.

To learn more, download our agenda. Register with code XP1951BLOG and receive 15% off of the standard rate. If you have any questions about the event, feel free to contact Kate Devery (Kdevery@iirusa.com) For more information visit our homepage. We hope to see this March!

Cheers,
The Government Programs Team

Opt-in for GP updates
GP Twitter
GP LinkedIn

Download the Full Brochure For IIR's Gross-To-Net Accounting Forum

IIR’s 2nd Annual Gross-To-Net Accounting Forum for Pharmaceutical Manufacturers, taking place on June 17-18th in Philadelphia, is back by popular demand! Join branded and generic manufacturers and large, medium and small pharma to learn how to calculate liability and predict channel shifts through a collaborative GTN process.

2014 Highlights include:

• New tailored discussion groups to collaborate across Managed Markets, Commercial, Government Programs and Finance for Big, Small to Mid-Sized Pharma, and Generics
• First opportunity to get up close and personal with the AMP Final Rule at the pre-conference workshop
• Never-before-heard case studies on GTN automation and chargeback methodology, in addition to strategic forecasting panel discussions
• Quantifying approaches for the impact of Medicaid, 340B and Healthcare Reform

To full our full program, download the 2014 brochure.

Register today using code XP1911BLOG and receive 15% off the standard rate. If you have any questions about the agenda or event, please contact Kate Devery at kdevery@iirusa.com or visit our webpage.

We look forward to seeing you June 17-18 in Philadelphia!

Best,
The Gross-to-Net Team

Opt-in for updates
Follow us on Twitter
GTN LinkedIn

Download the GP podcast featuring Chris Cobourn

Today's podcast features Chris Cobourn, Senior Vice President of Commercial Compliance for CIS. Cobourn discussed his thoughts on the industry, as well as the challenge of forecasting Medicaid and Medicaid Managed Care, Bona Fide Services Fees and Fair Market Values, and mergers and acquisitions.

View our highlights below:

So before we begin, what are your thoughts on what’s going on in the industry today, Chris?

Chris: We are very much all in a “hurry up and wait” mode, especially from the pharmaceutical manufacturer perspective with continued delays of the final rule. But yet it is still really important to be as proactive as possible in your planning because when it hits, it could be significant and you really have to be in a comfortable position feeling that you‟ve planned for it.

Why is it important to conduct a company-specific impact analysis of the final rule?

Chris: At a high level, I think if you were to take a look at the question that we get increasingly from the CEO and CFO level, especially in smaller-sized companies where they are more involved, the simple question is: “What will the final rule mean to us and what will it take to implement it?”

When you look at all the variables and the proposed rule, if they all happen – and some of the significant things happen like the build-up rule, expansion of Medicaid to Puerto Rico, some of those types of things – it‟s significant. It‟s significant system changes, it‟s significant data that you‟ll need, it‟s significant materiality impact. So, how do you plan when you don't know which of those components will be in the final rule?

To hear more, download the full podcast.

Want to join Chris and CIS this March at IIR's 6th Annual Government Programs Summit? Register with code XP1951BLOG and receive 15% off of the standard rate. To view our full program, download our brochure. We hope to see you March 26-28 in Philadelphia, PA!

Part D Coverage Gap Discount Program Challenges

This year, new price and coverage dynamics kick-in for the Coverage Gap Discount Program (CGDP), which means all beneficiaries who enter the coverage gap will pay less for generic and brand-name drugs, with providers, manufacturers and CMS making up for the change. As most plans offer no Part D Prescription Drug gap coverage, this leaves some manufacturers little or no time to validate submitted invoices, its corresponding detail data, and prepare for the subsequent forecasting and rebates.

At the upcoming IIR's 6th Annual GP Summit in March, hear from Shannon Bermudez, Principal Consultant, Revenue Management, Life Sciences at Paragon Solutions in the session, Practical Solutions Manufacturers can use to Manage Coverage Gap Discount Program Challenges. Understand the challenges the Coverage Gap Discount Program has presented to pharmaceutical manufacturers and get practical solutions to manage these challenges to efficiently process payments under the CGDP within these deadlines.

To learn more, download our agenda.

Register with code XP1951BLOG and receive 15% off of the standard rate. If you have any questions about the event, feel free to contact Kate Devery (Kdevery@iirusa.com) For more information visit our homepage. We hope to see this March!

Cheers,
The Government Programs Team

Opt-in for GP updates
GP Twitter
GP LinkedIn

HRSA Cmdr. Krista Pedley Provides 340B Update Preceding June Regulation

This March, IIR’s 6th Annual Government Programs Summit will once again welcome Cmdr. Krista M. Pedley, PharmD, MS, CDR, USPHS, Director, Office of Pharmacy Affairs, Health Resources and Services Administration, who will provide an update on the 340B program. The timing could not be better as a Memorandum Report released by the OIG this week spotlights inconsistencies within the 340B program.**

With the U.S. Department of Health and Human Services publishing the 340B proposed rule in June triggering an increase in transparency to the 340B program, you'll best prepare for the impact of these changes in the track - 340B Summit for Manufacturers, in collaboration with Apexus' 340B University. Hear updates and learn about the latest details in these key hot topic areas: Contract Pharmacies, Orphan Drugs, GPO Prohibition, Covered Outpatient Drugs, Audits, and more!

To learn more, download our agenda.

Register with code XP1951BLOG and receive 15% off of the standard rate. If you have any questions about the event, feel free to contact Kate Devery (Kdevery@iirusa.com) For more information visit our homepage. We hope to see this March!

Cheers,
The Government Programs Team

Opt-in for GP updates
GP Twitter
GP LinkedIn

Whitepaper: Minimizing Care Gaps for Individuals Churning between the Marketplace and Medicaid: Key State Considerations

Today's excerpt has been provided by Veronica Guerra and Shannon McMahon from Center for Health Care Strategies
Of the estimated 96 million Americans eligible to receive Medicaid or Marketplace subsidies during any given year, up to 29 million are likely to “churn” between all coverage options, and seven million are likely to experience coverage shifts between Medicaid and marketplace policies annually.1 Based on past experience, adults who change health insurance coverage are less likely to have a usual source of care and report delaying care during coverage transitions.2 Those who churn between Medicaid and the newly established marketplace will, at a minimum, have different benefits and out-of-pocket expenses (e.g., premiums and cost-sharing). Further changes in plans, provider networks, and eligibility status could result in a lack of care coordination, unmet needs, and/or an exacerbation of chronic conditions.3 In addition, high rates of churn across the new array of Medicaid-marketplace coverage options will put an increased administrative burden on states and contracting health plans.

Given the likely churn between Medicaid and the marketplace, states can take steps to ensure coverage and care coordination so health status does not deteriorate during these transitions. A handful of states have begun to estimate the potential magnitude of churn on their current and newly eligible populations, and are exploring options to mitigate churn. This brief, made possible through the Robert Wood Johnson Foundation, outlines concrete strategies for states to mitigate the impact of coverage transitions.

You can view the full article here. CHCS will be joining us May 19-21 in Baltimore, MD for IIR's Medicaid Managed Care Congress. To learn more, view our agenda. Want to hear more from CHCS? Register with code XP1926BLOG.